|Bid||105.68 x 800|
|Ask||108.40 x 900|
|Day's range||105.50 - 107.07|
|52-week range||63.22 - 107.71|
|Beta (5Y monthly)||0.27|
|PE ratio (TTM)||35.79|
|Forward dividend & yield||1.47 (1.45%)|
|Ex-dividend date||16 Aug 2021|
|1y target est||106.36|
With that in mind, let's turn our attention to two healthcare giants with excellent track records -- Medtronic (NYSE: MDT) and Novo Nordisk (NYSE: NVO) -- and see why both companies may be well worth holding onto for the years ahead. Like many other medical-device specialists, Medtronic had a rough go of it at the peak of the pandemic. Healthcare facilities swamped with COVID-19 patients postponed elective surgeries, leading to lower sales volume for some of Medtronic's products used by physicians.
Bagsværd, Denmark, 25 October 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme i
It's not that difficult to spread your investments out across many companies and hope for the best over a long time horizon. Another took a different route by making a bet on ARK Genomic Revolution ETF (NYSEMKT: ARKG) in the hope of owning the first healthcare industry trillion-dollar market cap company. Jason Hawthorne (Novo Nordisk): Novo Nordisk is one of three large drug manufacturers that account for the majority of insulin production in the world.